[Federal Register Volume 84, Number 218 (Tuesday, November 12, 2019)]
[Notices]
[Pages 61057-61058]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-24465]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[CDC-2019-0093; NIOSH-156-E]


Request for Information for Six Chemicals To Develop Immediately 
Dangerous to Life or Health (IDLH) Values.

AGENCY: National Institute for Occupational Safety and Health (NIOSH) 
of the Centers for Disease Control and Prevention (CDC), Department of 
Health and Human Services (HHS).

ACTION: Request for information.

-----------------------------------------------------------------------

SUMMARY: The National Institute for Occupational Safety and Health 
(NIOSH) of the Centers for Disease Control and Prevention (CDC) intends 
to evaluate the scientific data for 6 chemicals--allyl alcohol, bromine 
chloride, hydrogen bromide, hydrogen iodide, lewisite (a chemical 
warfare agent), and propylene imine--to develop new or updated 
Immediately Dangerous to Life or Health (IDLH) values.

DATES: Electronic or written comments must be received by January 13, 
2020.

ADDRESSES: You may submit comments, identified by CDC-2019-0093 and 
Docket Number NIOSH-156-E, by either of the two following methods:
     Federal eRulemaking Portal: http://www.regulations.gov. 
Follow the instructions for submitting comments.
     Mail: NIOSH Docket Office, Robert A. Taft Laboratories, 
MS-C34, 1090 Tusculum Avenue, Cincinnati, OH 45226.
    Instructions: All information received in response to this notice 
must include the agency name and docket number (CDC-2019-0093; NIOSH-
156-E). All relevant comments received will be posted without change to 
http://www.regulations.gov, including any personal information 
provided. All electronic comments should be formatted in Microsoft 
Word. Please make reference to CDC-2019-0093 and Docket Number NIOSH-
156-E.

FOR FURTHER INFORMATION CONTACT: R. Todd Niemeier, MS, NIOSH, MS-C32, 
1090 Tusculum Avenue, Cincinnati, OH 45226, telephone (513) 533-8166.

SUPPLEMENTARY INFORMATION: In 2013, NIOSH published Current 
Intelligence Bulletin (CIB) 66--Derivation of Immediately Dangerous to 
Life or Health (IDLH) Values [http://www.cdc.gov/niosh/docs/2014-100/pdfs/2014-100.pdf] [NIOSH 2013]. The information presented in this CIB 
represents the most recent update of the scientific rationale and the 
methodology (hereby referred to as the IDLH methodology) used to derive 
IDLH values. Since the establishment of the IDLH values in the 1970s, 
NIOSH has continued to review available scientific data to improve the 
protocol used to derive acute exposure guidelines, in addition to the 
chemical-specific IDLH values.
    IDLH values are based on health effects considerations determined 
through a critical assessment of the toxicology and human health 
effects data. This approach ensures that the IDLH values reflect an 
airborne concentration of a substance that represents a high-risk 
situation that may endanger workers' lives or health.
    The primary steps applied in the establishment of an IDLH value 
include the following:
    1. Critical review of human and animal toxicity data to identify 
potentially relevant studies and characterize the various lines of 
evidence that can support the derivation of the IDLH value;
    2. Determination of a chemical's mode of action (MOA) or 
description of how a chemical exerts its toxic effects;
    3. Application of duration adjustments (time scaling) to determine 
30-minute-equivalent exposure concentrations and the conduct of other 
dosimetry adjustments, as needed;
    4. Experimental or other data to establish a point of departure 
(POD) such as lethal concentrations (e.g., LC50), lowest observed 
adverse effect level (LOAEL), or no observed adverse effect level 
(NOAEL);
    5. Selection and application of an uncertainty factor (UF) for POD 
or critical adverse effect concentration, identified from the available 
studies to account for issues associated with interspecies and 
intraspecies differences, severity of the observed effects, data 
quality, or data insufficiencies; and
    6. Development of the final recommendation for the IDLH value from 
the various alternative lines of evidence, with use of a weight-of-
evidence approach to all of the data.
    NIOSH seeks to obtain materials, including published and 
unpublished reports and research findings, to evaluate the possible 
acute health risks of occupational exposure to the following six 
chemicals:

1. Allyl Alcohol (CAS# 107-18-6)
2. Bromine Chloride (CAS# 13863-41-7)
3. Hydrogen Bromide (CAS# 10035-10-6)
4. Hydrogen Iodide (CAS# 10034-85-2)
5. Lewisite (a chemical warfare agent) (CAS#s 541-25-3, 40334-69-8, 
40334-70-1)
6. Propylene Imine (CAS# 75-55-8)

    Materials also include reports of acute animal toxicity studies, 
acute human toxicology studies, mode of action studies, and other 
information about a chemical's toxic effects such as studies on sensory 
or respiratory irritation, nervous system effects (e.g., dizziness, 
central nervous system excitability, autonomic effects, muscle tone/
equilibrium effects, sensorimotor reactivity, nervous system 
histopathology), metabolic toxicants, target organ toxicants, 
gastrointestinal effects, cardiovascular changes, and asphyxiants.

[[Page 61058]]

    In a subsequent notice, Draft IDLH Value profiles for these 
chemicals will be made available for public comment.

Reference

    NIOSH [2013]. Current intelligence bulletin 66: derivation of 
immediately dangerous to life or health (IDLH) values. Cincinnati, OH: 
US Department of Health and Human Services, Centers for Disease Control 
and Prevention, National Institute for Occupational Safety and Health, 
DHHS (NIOSH) Publication 2014-100.

John J. Howard,
Director, National Institute for Occupational Safety and Health, 
Centers for Disease Control and Prevention.
[FR Doc. 2019-24465 Filed 11-8-19; 8:45 am]
 BILLING CODE 4163-18-P